Download PDF
Thromb Haemost 1967; 18(01/02): 268-275
DOI: 10.1055/s-0038-1655035
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Turnover of 131I-Fibrinogen in Mercury Chloride Intoxicated Dogs[*]

W Gałasinski
1   Department of Physiological Chemistry (Head: Doc. Dr. S. Niewiarowski) and Department of Physics (Head: Doc. Dr. E. Trembaczowski) Medical School, Bialystoic (Poland)
,
K Worowski
1   Department of Physiological Chemistry (Head: Doc. Dr. S. Niewiarowski) and Department of Physics (Head: Doc. Dr. E. Trembaczowski) Medical School, Bialystoic (Poland)
,
S Niewiarowski
1   Department of Physiological Chemistry (Head: Doc. Dr. S. Niewiarowski) and Department of Physics (Head: Doc. Dr. E. Trembaczowski) Medical School, Bialystoic (Poland)
,
G Franecki
1   Department of Physiological Chemistry (Head: Doc. Dr. S. Niewiarowski) and Department of Physics (Head: Doc. Dr. E. Trembaczowski) Medical School, Bialystoic (Poland)
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

The turnover of 131I-fibrinogen, studied in 15 normal dogs, amounted on the average to 2.6 days. The fibrinogen level considerably increased but the biological half-life time of 131I-fibrinogen was significantly shorter in mercury chloride intoxicated dogs, particularly in the first phase of intoxication.

It has been concluded that the fibrinolytic enzymes connected with kidney and depleted in intoxicated dogs are not essential for the fibrinogen catabolism. The elevation of fibrinogen in mercury chloride intoxication is not directly caused by the inhibition of fibrinolytic enzymes.

Possible explanations of the accelerated turnover of fibrinogen in HgCl2 treated dogs were discussed.

* Aided in part by the grants from the Biochemical and Biophysical Committee, Dept. II and from Dept. VI, Polish Academy of Sciences.


 

  • References

  • 1 Adelson E, Rheingold J. J, Parker O, Buenaventura A, Crosby W. H. Platelet and fibrinogen survival in normal and abnormal states of coagulation. Blood 17: 267 1961;
    PubMedGoogle Scholar
  • 2 Amris A, Amris C. J. Turnover and distribution of iodine labelled human fibrinogen. Thrombos. Diathes. haemorrh. (Stuttg) 11: 404 1964;
    PubMedGoogle Scholar
  • 3 Astrup T, Sterndorff I. Fibrinolysokinase activity in animal and human tissue. Acta physiol, scand 37: 41 1956;
    PubMedGoogle Scholar
  • 4 Attencio A. G, Burdick D. G, Reeve E. B. An accurate isotope dilution method for measuring plasma fibrinogen. J. Lab. clin. Med. 66: 137 1965;
    PubMedGoogle Scholar
  • 5 Attencio A. C, Reeve E. B. Studies on the metabolism and distribution of fibrinogen in young and older-rabbits. II. Results. J. Lab. clin. Med. 66: 20 1965;
    PubMedGoogle Scholar
  • 6 Blombäck B, Carlson L. A, ranzen S. F, Zetterquist E. Turnover of 131I-labelled fibrinogen in man. Acta med. scand. 179: 557 1966;
    PubMedGoogle Scholar
  • 7 Buluk K, Furman M. On the controlling function of the kidneys in fibrinolysis. Experientia (Basel) 18: 146 1962;
    CrossrefPubMedGoogle Scholar
  • 8 Buluk K, Matofiejew M. Otrzymywanie aktywatora fibrynolizy w nerce poza ustrojem (aktywator fibrynolizy w izolowanej nerce. Acta physiol, pol. 14: 371 1963;
    PubMedGoogle Scholar
  • 9 Budzynski A. Doctor Thesis. Institute of Nuclear Research; Warsaw: 1962
    Google Scholar
  • 10 Devakul K, Harinasuta T, Reid H. A. 125I-labelled fibrinogen in cerebral malaria. Lancet II: 886 1966;
    PubMedGoogle Scholar
  • 11 Egeberg O. Blood coagulation in renal failure. Scand. J. clin. Lab. Invest 14: 163 1962;
    CrossrefPubMedGoogle Scholar
  • 12 Gajewski J, Alexander B. Effect of epsilon-aminocaproic acid on the turnover of labelled fibrinogen in rabbits. Circulât. Res. 13: 432 1963;
    PubMedGoogle Scholar
  • 13 Gross R, Nieth H, Mammen E. Blutungsbereitschaft und Gerinnungsstörungen bei Urämie. Klin. Wschr. 36: 107 1958;
    CrossrefPubMedGoogle Scholar
  • 14 Hart H Ch. The biological half-life of 131I-fibrinogen in “Genetics and interaction of blood clotting factors”. 121 F. K. Schattauer; Stuttgart: 1965
    Google Scholar
  • 15 Kekwick R. A, Mackay M. E, Nance M. H, Record B. R. The purification of human fibrinogen. Biochem. J. 60: 671 1955;
    PubMedGoogle Scholar
  • 16 Koffler D, Paronetto F. Immunofluorescent localization of immunoglobulins, complement and fibrinogen in human disease. II. Acute, subacute and chronic glomerulonephritis. J. clin. Invest 44: 1665 1965;
    PubMedGoogle Scholar
  • 17 Bidstrup PLesley. Toxicity of mercury and its compounds. Elsevier: Amsterdam; 1964
    Google Scholar
  • 18 Lewis J. H. Effects of epsilon-aminocaproic acid on survival of fibrinogen-131I and fibrinolytic and coagulation factors in dogs. Proc. Soc. exp. Biol. (N. Y) 114: 111 1963;
    PubMedGoogle Scholar
  • 19 Lewis J. H, Ferguson E. E, Schoenfeld C. Studies concerning the turnover of fibrinogen-131I in the dog. J. Lab. clin. Med. 58: 247 1961;
    PubMedGoogle Scholar
  • 20 Lewis J. H, Zucker M. B, Ferguson J. H. Bleeding tendency in uremia. Blood 11: 1073 1965;
    PubMedGoogle Scholar
  • 21 Madden R. E, Gould R. G. Turnover rate of plasma fibrinogen. Fed. Proc. 11: 252 1952;
    PubMedGoogle Scholar
  • 22 McConnell P, Johnson J. G, Young I, Holemans R. Localization of plasminogen activator in kidney tissue. Lab. Invest 15: 980 1966;
    PubMedGoogle Scholar
  • 23 McFarlane A. S, Todd D, Cromvell S. Fibrinogen degradation in humans. Clin. Sci. 26: 415 1964;
    PubMedGoogle Scholar
  • 24 Niewiarowski S, Prokopowicz J, Poplawski A, Worowski K. Inhibition of dog fibrinolytic system in experimental tubular necrosis of kidney. Experientia (Basel) 02: 99 1964;
    PubMedGoogle Scholar
  • 25 Nowak A, Zahorska-Markiewicz B. Aktywnosc urokinazy i fibrynoliza w chorobach nerek. Pol. Arch. Med. wewnet. 35: 653 1965;
    PubMedGoogle Scholar
  • 26 Prokopowicz J, Rejniak L, Niewiarowski S, Worowski K. Fibrinolytic activity of tissue sections of dog kidney. Thrombos. Diathes. haemorrh. (Stuttg) 12: 396 1964;
    PubMedGoogle Scholar
  • 27 Quick A. J. The physiology and pathology of haemostasis. Kimpton, London: 1951
    Google Scholar
  • 28 Rausen A. R, Cruchaud A, McMillan G. W, Gitlin D. A study of fibrinogen turnover in classical hemophilia and congenital afibrinogenemia. Blood 18: 710 1961;
    PubMedGoogle Scholar
  • 29 Rogoeczi E, Rogoeczi G. E, McFarlane A. S. Relation between rate of catabolism, plasma concentration and pool size of fibrinogen. Pflügers Arch. ges. Physiol. 279: 17 1964;
    CrossrefPubMedGoogle Scholar
  • 30 Regoeczi E. L, Henley G. E, Holloway R. C, McFarlane A. S. Turnover of 131I-labelled fibrinogen in fever. Brit. J. exp. Path. 44: 397 1963;
    PubMedGoogle Scholar
  • 31 Regoeczi E, Gergely J, McFarlane A. S. In vivo effects of Agkistrodon rhodostoma venom: studies with fibrinogen-131I. J. clin. Invest 45: 1202 1966;
    CrossrefPubMedGoogle Scholar
  • 32 Schultz F. H. Das Fibrinogen. VEB Georg Thieme; Leipzig: 1953
    Google Scholar
  • 33 Takeda Y, Reeve E. B. Fibrinogen metabolism in patients with rheumatoid arthritis. Fed. Proc. 42: 386 1965;
    PubMedGoogle Scholar
  • 34 Truax W. E, McCoy J. Gamma globulin catabolism by the kidney. Tex. Rep. Biol. Med. 23: 793 1965;
    PubMedGoogle Scholar
  • 35 Vassalli P, Morris R. H, McCluskey R. T. The pathogenic role of fibrin deposition in the glomerular lesions of toxemia of pregnancy. J. exp. Med. 118: 467 1963;
    CrossrefPubMedGoogle Scholar
  • 36 Vassalli P, McCluskey R. T. Editorial. The coagulation process and glomerular disease. Amer. J. Med. 39: 179 1965;
    PubMedGoogle Scholar
  • 37 Wiliams J. R. B. The fibrinolytic activity of urine. Brit. J. exp. Path. 32: 530 1951;
    PubMedGoogle Scholar
  • 38 Worowski K. Unpublished results..
    PubMedGoogle Scholar
  • 39 Worowski K, Niewiarowski S, Prokopowicz J. Fibrinolysis and fibrinogen breakdown products (antithrombin VI) in renal venous blood (RVB) in dog. Thrombos. Diathes. haemorrh. (Stuttg) 12: 87 1964;
    PubMedGoogle Scholar